Effect of Domuvar in an experimental model of irritable bowel syndrome
Main Article Content
Abstract
This study was conducted to evaluate the protective and curative effects of Domuvar on an experimental model of irritable bowel syndrome. Domuvar contains Bacillus subtilis with the indication of supporting the symptomatic treatment of gastrointestinal diseases. Swiss mice were divided into 6 groups, in which groups 1 - 3 were given orally distilled water, group 4 were given orally mebeverine, groups 5 - 6 were given orally Domuvar at two doses of 0.82 x 109 CFU/kg/day and 1.64 x 109 CFU/kg/day. Mustard oil was used to induce irritable bowel syndrome with diarrhea in mice of groups 3-6 before oral treatment (to evaluate the curative effect) or after oral treatment (to evaluate the protective effect). Our results showed that Domuvar at 1.64 x 109 CFU/kg/day had the effect of reducing intestinal motility as shown by reducing activated charcoal mobility in the intestine and improving stool condition. In conclusion, Domuvar has protective and curative effects on the experimental model of irritable bowel syndrome with diarrhea in mice.
Article Details
Keywords
Bacillus subtilis, Swiss mice, irritable bowel syndrome with diarrhea, mustard oil
References
2. Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(10): 908-917. doi:10.1016/S2468-1253(20)30217-X.
3. Sebastián Domingo JJ. Irritable bowel syndrome. Med Clin. 2022; 158:76-81.
4. Hellström PM. Pathophysiology of the irritable bowel syndrome - Reflections of today. Best Pract Res Clin Gastroenterol. 2019; 40-41:101620.
5. Bonetto S, Fagoonee S, Battaglia E, et al. Recent advances in the treatment of irritable bowel syndrome. Pol Arch Intern Med. 2021; 131(7-8): 709-715. doi:10.20452/pamw.16067.
6. World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics. 2023.
7. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010; 59: 325-32. doi: 10.1136/gut.2008.167270.
8. Manoj AS, Varun PS, Dharmesh BK. Novel insight on probiotic Bacillus subtilis: Mechanism of action and clinical applications. J Curr Res Sci Med. 2016; 2:65-72. doi: 10.4103/2455-3069.198381.
9. Kimball ES, Palmer JM, D’Andrea MR, et al. Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice. Am J Physiol Gastrointest Liver Physiol. 2005; 288(6): G1266-1273. doi:10.1152/ajpgi.00444.2004.
10. Waugh A, Foshaug R, Macfarlane S, et al. Effect of Lactobacillus plantarum 299v treatment in an animal model of irritable bowel syndrome. Microbial Ecology in Health & Disease. 2009;21. doi:10.3402/mehd.v21i1.7572.
11. Crisan IM, Dumitrascu DL. Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications. Clujul Med. 2014; 87(2): 73-79. doi:10.15386/cjmed-269.
12. Jaroslaw D, Ewa MW, Barbara SR, et al. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome - A Systematic Review. J Clin Med. 2022; 11(4): 1044. doi: 10.3390/jcm11041044.
13. Yi Gong, Hui Li, and Yan Li. Effects of Bacillus subtilis on Epithelial Tight Junctions of Mice with Inflammatory Bowel Disease. J Interferon Cytokine Res. 2016; 36(2): 75-85. doi: 10.1089/jir.2015.0030.
14. Maria CU, Marie L, Guylene L, et al. Antidiarrheal Action of Bacillus subtilis CU1 CNCM I-2745 and Lactobacillus plantarum CNCM I-4547 in Mice. Front Microbiol. 2018; 9:1537. doi: 10.3389/fmicb.2018.01537